Valuation: Novartis AG

Market Cap 277B 4,815B 242B 223B 205B 389B 26,644B 396B 2,666B 1,046B 13,023B 1,040B 1,017B 44,886B P/E 2026 *
21.1x
P/E 2027 * 17.9x
Enterprise Value 309B 5,371B 270B 249B 229B 434B 29,723B 441B 2,974B 1,167B 14,528B 1,160B 1,135B 50,074B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 5.06x
Free-Float
91.66%
Yield 2026 *
2.91%
Yield 2027 * 3%
1 day+0.62%
Current month+0.62%
1 month+5.42%
3 months+2.81%
6 months+7.28%
Current year+9.68%
1 month 2,563
Extreme 2563
2,742
Current year 2,479
Extreme 2479
2,866.83
1 year 2,206
Extreme 2206
2,866.83
3 years 1,540
Extreme 1540
2,866.83
5 years 1,520
Extreme 1520
2,866.83
10 years 1,320.81
Extreme 1320.81
2,866.83
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%0.00% - - 277B
+0.35%-4.87%+49.87%+157.34% 1,031B
-2.69%-6.22%+59.19%+54.51% 595B
-0.27%-3.41%+30.97%+79.48% 431B
-0.44%-1.91%+28.45%+22.71% 326B
-0.94%-6.80%+19.26%+22.02% 263B
+1.01%+4.86%-22.58%-37.37% 224B
+0.86%-2.63%+22.50%+57.55% 193B
+1.28%-3.03%+20.76%+70.62% 164B
+2.35%+3.20%+0.85%-31.66% 141B
Average +0.20%-3.09%+23.25%+43.91% 374.32B
Weighted average by Cap. -0.18%-4.09%+34.78%+74.80%

Financials

2026 *2027 *
Net sales 56.91B 989B 49.75B 45.9B 42.19B 79.94B 5,476B 81.31B 548B 215B 2,676B 214B 209B 9,225B 60.31B 1,049B 52.73B 48.64B 44.71B 84.72B 5,803B 86.17B 581B 228B 2,836B 226B 222B 9,776B
Net income 14.08B 245B 12.31B 11.36B 10.44B 19.78B 1,355B 20.12B 136B 53.19B 662B 52.87B 51.71B 2,282B 15.64B 272B 13.68B 12.62B 11.6B 21.98B 1,505B 22.35B 151B 59.1B 736B 58.75B 57.46B 2,536B
Net Debt 32B 556B 27.98B 25.81B 23.73B 44.96B 3,079B 45.73B 308B 121B 1,505B 120B 118B 5,188B 28.5B 496B 24.92B 22.99B 21.13B 40.04B 2,743B 40.72B 274B 108B 1,340B 107B 105B 4,620B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
151.27USD
Average target price
153.17USD
Spread / Average Target
+1.26%

Quarterly revenue - Rate of surprise